SCHEMBL5457615

SCHEMBL5457615

NC(=O)c1c(NC(=O)C2CC2COCc2ccccc2)sc2c1CCOC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.50
FLT3 P36888 4/20 0.48
RAB7A P51149 1/20 0.44
POLB P06746 2/20 0.44
CASP6 P55212 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
RECQL P46063 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CXCR2 P25025 1/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
PTPRC P08575 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450939 0.81 CFTR (0.54) CFTRFLT3POLBCASP6TDP1
SCHEMBL14361079 0.80 CFTR (0.56) CFTRFLT3POLBCASP6TDP1
SCHEMBL5452383 0.80 LMNA (0.57) CFTRFLT3RAB7APOLBCASP6
SCHEMBL5457472 0.79 CFTR (0.52) CFTRFLT3POLBCASP6TDP1
SCHEMBL5453253 0.78 CFTR (0.53) CFTRFLT3POLBCASP6TDP1
SCHEMBL5465704 0.76 NPC1 (0.51) CFTRFLT3RAB7AALDH1A1MAPT
SCHEMBL5452084 0.76 ALDH1A1 (0.55) CFTRFLT3POLBCASP6TDP1
SCHEMBL5466126 0.76 CFTR (0.57) CFTRFLT3POLBCASP6TDP1
SCHEMBL5460380 0.76 CFTR (0.60) CFTRFLT3POLBCASP6TDP1
SCHEMBL5451008 0.74 CFTR (0.59) CFTRFLT3RAB7AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885FLT3 3509/4885RAB7A 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.